Table of Contents Author Guidelines Submit a Manuscript
Schizophrenia Research and Treatment
Volume 2011, Article ID 614730, 10 pages
http://dx.doi.org/10.1155/2011/614730
Review Article

Dissecting the Syndrome of Schizophrenia: Progress toward Clinically Useful Biomarkers

1The Rebecca L. Cooper Research Laboratories, The Mental Health Research Institute, Locked bag 11, Parkville, VIC 3052, Australia
2The Department of Psychiatry, The University of Melbourne, Parkville, VIC 3052, Australia

Received 18 December 2010; Revised 28 March 2011; Accepted 7 April 2011

Academic Editor: Vaibhav A. Diwadkar

Copyright © 2011 Brian Dean. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The search for clinically useful biomarkers has been one of the holy grails of schizophrenia research. This paper will outline the evolving notion of biomarkers and then outline outcomes from a variety of biomarkers discovery strategies. In particular, the impact of high-throughput screening technologies on biomarker discovery will be highlighted and how new or improved technologies may allow the discovery of either diagnostic biomarkers for schizophrenia or biomarkers that will be useful in determining appropriate treatments for people with the disorder. History tells those involved in biomarker research that the discovery and validation of useful biomarkers is a long process and current progress must always be viewed in that light. However, the approval of the first biomarker screen with some value in predicting responsiveness to antipsychotic drugs suggests that biomarkers can be identified and that these biomarkers that will be useful in diagnosing and treating people with schizophrenia.